Radiopharm Theranostics Ltd (RADX) stock

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30

$0.76−0.03 (-3.80%)

Close on Nov 13, 2026Market cap $8.98MP/E –Yield –

Radiopharm Theranostics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2026 it was -$54.08M.

Period	Period end	Value	Change
FY2026	Jun 30, 2026	-$54.08M	–
FY2025	Jun 30, 2025	-$35.58M	–
FY2024	Jun 30, 2024	-$44.08M	–
FY2023	Jun 30, 2023	-$31.19M	–

Parsed from the XBRL in Radiopharm Theranostics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is RADX.

Revenue growth-23.8% · median 33.9%

Operating margin-2051.5% · median -353.2%

Advertisement
300 × 250

See a number that looks wrong?